Internet Drug
Pharmaceutical News & Information; Updated Daily

Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

9/29 Feds to Mylan: You Got the Rebate Wrong
U.S. agency says it advised Mylan that EpiPen was misclassified .... Mylan classified the EpiPen with the Medicaid Drug Rebate Program as a non-innovator multiple source drug, which pays a rebate of 13 percent to states, rather than innovator, which pays a rebate of a minimum of 23.1 percent .... Reuters

9/29 Dramatic Change in Mix of Diabetes Drugs Used; Many Patients Still Lack Control
Changes in Use of Glucose-Lowering Drugs From 2006-2013 .... The researchers observed an increase in use of metformin, dipeptidyl peptidase-4 inhibitors, and insulin, and a decline in use of sulfonylureas and thiazolidinediones, from 2006 to 2013 (all P < 0.001) .... HealthDay News

9/29 Payers 'Go Where the Money Is' and Don't Focus on High-Ticket Drugs for Small Populations
Most insurers unfazed by high price of orphan drugs .... Payers seem "more focused on larger categories where there is more need to manage costs," including cancer, diabetes, and hepatitis drugs. To wit, only 17 percent of the payers reported aggressively managing orphan drug costs and do not plan to do so in the foreseeable future .... Stat/Pharmalot

9/29 3 Potential Blockbusters on Deck
3 Critical FDA Decisions You Can't Afford to Miss .... The FDA already has nearly three dozen PDUFA decisions scheduled between now and the end of February 2017 .... Motley Fool

9/29 Advocates Say Drug Prescription Databases Drive Addicts to Street Drugs
Drug databases are no panacea for opioid crisis .... While critics say the drug databases impinge on civil liberties, others battling the opioid crisis say their effectiveness varies. Depending on software design, new prescriptions pop up in the databases anywhere from five minutes to a week after the pharmacy fills them .... Politico

9/29 Patient Groups Afraid to Bite the Hand
Furor Over Drug Prices Puts Patient Advocacy Groups in Bind .... The Leukemia & Lymphoma Society, for instance, one of the largest charities in the United States, has frequently criticized insurers for exposing patients to high out-of-pocket costs for patients, commissioning two studies that looked at the impact of these high costs. But it has not been as outspoken about the decision by drug companies to set those prices .... NY Times

9/29 Broad Insurance Coverage Expected for Eteplirsen Despite Price Tag
Doctors ready to roll with Sarepta's $300K DMD med Exondys 51. Are payers? .... Only 5% of the surveyed neurologists said they don't plan to use the drug, and 40% said they'll use it in all or most of their eligible patients .... Fierce Pharma

9/29 Markey Wants FTC Action on Indivior
Senator urges FTC to step up investigation into maker of addiction treatment .... A US senator is urging the US FTC to accelerate its antitrust investigation into a drug maker that sells Suboxone, a medicine used to treat addiction to opioids and narcotics .... Stat/Pharmalot

9/29 CDC Zika Test Infighting
CDC whistleblower claims agency has been using wrong Zika test .... Lanciotti was demoted in May after he raised concerns inside and outside the agency about the CDC's decision in the spring to recommend a new test for Zika. That test is substantially less effective than another established test and misses nearly 40 percent of Zika infections .... Washington Post

9/29 Internet Drug News Fast Takes:
Artificial Pancreas Approved by FDA Marks a Global First
Aetna to offer Apple Watch at a discount to certain customers
One upside to the drug price pressure debate: more biopharma deals
Med City News
FDA's Clinical Investigator Training Helps Support the Drug Development Process
FDA Blog
Hub appeal: AstraZeneca is marshaling 350-plus R&D troops in new South San Francisco campus
Has Your Health Care Company Updated Its Business Associate Agreements?
Bloomberg BNA
FDA Accepts Application for Osteoporosis Drug Romosozumab

9/28 Kyprolis Can't Beat Velcade in Multiple Myeloma
Amgen's Myeloma Drug Doesn't Top Takeda's in First-Line Use .... Patients taking Kyprolis with the chemotherapy drug melphalan and prednisone, a steroid, lived for a median of 22.3 months without their disease progressing.... That compared to 22.1 months for patients taking Takeda's Velcade along with melphalan and prednisone .... Bloomberg

9/28 Opdivo to Combo with PD-1 Enhancer Nektar's NKTR-214
Bristol-Myers to test Opdivo with Nektar drug for several cancers .... The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer .... Reuters

9/28 Early Success for CAR T-cell Therapy
Kite immunotherapy drug helps blood cancer patients in study .... Some 76 percent of patients taking the drug, called KTE-C19, showed significant tumor shrinkage, including 47 percent who had no remaining signs of cancer at least three months after receiving the treatment .... Reuters

9/28 High Hopes (and Hype) for Avelumab
Is This Pfizer's Next Mega-Blockbuster Cancer Drug? .... The fate of one of avelumab's most valuable indications -- first line non-small cell lung cancer -- should be known by the fourth quarter of 2017. That means that Pfizer's fledgling immuno-oncology franchise could get its first real test in the regulatory arena -- and perhaps this increasingly crowded market, as well -- in 2018 .... Motley Fool

9/28 Gilead's Hep C revenue Could be Down 90% by 2020
As hep C proves a 'flash in the pan' once again, Gilead's sales will 'erode massively': Analyst .... Gilead's high-flying franchise has seen sales drop to the point where investors are demanding a fix via M&A. Leerink Partners has cut its revenue forecast for the company's hep C drugs--Sovaldi, Harvoni, and now, Epclusa--by a hefty $2 billion to $2.5 billion per year after 2017 .... Motley Fool

9/28 Who Gets to Cash In?
From FDA expert to biotech insider: The drug industry thrives on the revolving door .... More than half of the FDA hematology-oncology assessors who reviewed drugs between 2001 and 2010 went on to work for the biopharmaceutical industry .... Stat

9/28 Specialty Pharmacies Growing Like Wildfire
2015's Fastest-Growing, Private Specialty Pharmacies (From the Inc. 5000) .... Average (median) 2015 revenue for these 12 businesses was $265 million ($127 million), and the average 3-year revenue growth rate was 1,440% (401%) .... Drug Channels

9/28 Hospitals Bet that Filling the Transportation Gap Will Pay Off
Uber partners with startup to take patients to the doctor .... A 2005 study estimated that 3.6 million people do not receive nonemergency medical care because they don't have access to transportation.... patients with a high burden of chronic diseases are more likely to struggle with getting transportation to a doctor's appointment. .... MM&M

9/28 FDA Will Redefine What 'Healthy' Means in Regards to Food
FDA Takes Step Toward New "Healthy' Labeling .... Under the current definition, food makers can only claim their product is healthy if it meets criteria for being low in fat, saturated fat, sodium and cholesterol, while having a certain amount of beneficial nutrients, such as vitamin C or Calcium. Frosted Flakes cereal would be considered healthy because they meet all the criteria, from low fat to fortified with vitamins, while almonds and avocados aren't .... WSJ

9/28 New Indication for Stelara
FDA approves J&J's autoimmune drug Stelara for Crohn's disease .... Late-stage trial data showed Stelara induced remissions in moderate-to-severe Crohn's disease patients who had previously failed to benefit from TNF inhibitors .... Reuters

9/28 Internet Drug News Fast Takes:
ADHD drugs no help with homework
Reuters Health
Millennials say they're too busy to focus enough on their health
Advisory Board
New York Fertility Doctor Says He Created Baby With 3 Genetic Parents
NPR Health Blog
Martin Shkreli is auctioning off a chance to punch him in the face
SF Gate
Site experience makes Amazon first with consumers in product search
Drug Store News

Fast Takes
FDA deals out pain, handing out its third punishing slap down for opioid Remoxy
Endpoints News
Can You Guess Which Big Pharma Has Raised Its Drug Prices 5 Times Since June 2014?
Motley Fool
AbbVie digs in for a long war as Amgen bags first OK for a Humira biosimilar
Endpoints News
Mylan, Lupin Said to Weigh Bids for Bayer Dermatology Business

9/27 $600 Million In Fees Later, Pfizer Decides No To  Split Up
- Prefers bolt-on buyouts of $14 Billion or less
Pfizer Remains Whole, but the Option to Split Could Return … series of deals worth more than $220 billion had really only proved that the bigger the business, the more difficult it is to find new drugs …  last two years in purchasing Hospira for $15 billion; Medivation for $14 billion; and Anacor, a dermatology company, for $5 billion .. [NY Times]

Investors Displeased Glaxo's New CEO Is Glaxo Insider
- Dislike promotion of OTC chief Emma Wesley to CEO
Investor anger mounts over GSK's choice of chief executive … investors would have rather seen an external candidate appointed, and believe the promotion signals Ms Walmsley is unlikely to deviate …[Telegraph]
GSK's boss is smashing the glass ceiling, but not everybody's happy … [Telegraph]

Pill To Make Women Horny Flops: Valeant Suffers
- Analyst hints Addyi  may not be Valeant's only loser product
What's next for Valeant's Sprout biz? A huge impairment charge, analyst predicts … shelled out $1 billion to gain access to … in July, they had reached just $696,235 … far cry from the $100 million to $150 million the Canadian drugmaker forecast for this year … [Fierce Pharma]

FDA Rejects Supposedly Abuse Resistant Narcotic Analgesic
The FDA denies approval of abuse-deterrent opioid after promotional warning … Three weeks after the FDA's Office of Prescription Drug Promotion warned two drugmakers about promoting an unapproved painkiller, the regulator declined to approve that drug …[MMM Online]

Most Experimental Diabetes Drugs Are Flops
- Only 8% of candidates make it to drugstore shelves
Diabetes drugs are badly needed, but rarely make it to market … Only 1 in 13 investigational diabetes drugs that entered clinical testing from 1995 to 2007 ultimately received regulatory approval … risk level associated with new drug approvals is higher than it has ever been … [Pharmalot]

Sanofi Med For Eczema Gets Fast Track Review
- Could do $5 Billion per year
Regeneron, Sanofi get priority review, March 29 PDUFA date for atopic dermatitis drug … outperformed placebo and the standard of care in terms of clearing skin lesions … adverse events and infections were more common in the placebo arm than the dupilumab cohort … [Fierce Biotech]

WSJ Hints Mylan CEO Mislead Congress In Epi-Pen Testimony
- Repeatedly claimed Mylan made only $50 per Epi Pen but that's not entirely true
Mylan's EpiPen Pretax Profits 60% Higher Than Number Told to Congress … "Without the tax-related reduction, Mylan's profits on the EpiPen two-pack would be closer to $160, or 60 percent higher than the figure the company gave Congress … [WSJ]
Whoops, Mylan Underreported EpiPen Profits To Congress …  per CNBC, those profits cited before Congress were a tad under the real value-at least 4% and up to 66% lower than the value cited to the committee …[Forbes]
See Also: Lawmaker: 'We don't believe' Mylan on new profit numbers for EpiPens … [CNBC]

Fast Takes
Thumbs Up/Thumbs Down: The FDA damaged itself badly with the Sarepta OK
Endpoints News
Generics or Specialty: Which Mylan Segment Is Growing Fastest?
Market Realist
FDA Approves Ammgen's Humira Biosimilar; OK'd for same indications as adalimumab
MedPage Today
Is Insulin The Next Epi Pen?
Next Drug Price Scandal Could Be Cost of Naloxone
The Street
Lundbeck says much anticipated Alzheimer's drug fails in late-stage study
Fox News
FDA's Dangerous Deals With Reporters

4,200% Price Increase; Skin Cream Goes From $226 to $9,500
- Noted Journalist Uncovers Two More Price Gouge Poster Children
The curious case of the $9,500 skin gel … Two months after it acquired them, it jacked up the prices ... Alcortin A, a gel used to treat dermatitis and eczema, went from $226 to $2,995 … this month, Novum boosted prices again. Alcortin A and Aloquin each now list for $9,561…[Pharmalot]

Drugmaker Price Gouging Takes Center Stage In Presidential Race
- Not Obamacare; candidates target pharma industry to score election points
As Clinton-Trump Debate Looms, It's Drug Prices, Not Obamacare, Taking Stage … series of missteps on pricing everything from heart medications to EpiPens could enter the presidential crossfire … Affordable Care Act has so far taken a backseat role to drug pricing in this presidential election cycle …[Forbes]

Is Valeant Pharmaceuticals Playing With Fire?
- Valeant's management team may not have learned its lesson after all.
Is Valeant Pharmaceuticals Playing With Fire? … Valeant recently raised the list price of three of its products by 9.9% … hospital executives claim that Valeant hasn't followed through with the discounts it had promised on Nitropress and Isuprel … []

Mylan CEO: Blame The PBMs; They Pocketed Epi Pen Bonanza
Where Did All That EpiPen Money Go? … heme of Ms. Bresch's testimony was that the PBMs were squeezing her poor little drug company (revenues of $9.4 billion last year and on pace to beat $10 billion easily) half to death, forcing these nasty price hikes … Rebates are de

9/23 Stat's Investigative Reporting Pays Off; Court Documents Reveal Abbott's Role In OxyContin Promotion
Secret trove reveals bold 'crusade' to make OxyContin a blockbuster .... But the role of Abbott in pushing the drug has largely escaped notice. The documents reveal it was a crucial partner in the aggressive — and misleading — selling of OxyContin during its first decade on the market. .... Stat

9/23 Sales Growth Slows in Emerging Markets
Hard to swallow: emerging markets get tougher for drugmakers .... Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent .... Reuters/Ben Hirschler

9/23 "Possibly Effective" Acne Cream Now At $10,000
The newest pharma villain Novum is charging $9,561 for a tube of skin cream .... Aloquin is used to treat acne and eczema, and is made with ingredients that can be bought at a pharmacy for less than $40, according to the FT. The US Food and Drug Administration calls it "possibly effective." .... Quartz

9/23 Eteplirsen Will Be Covered Despite Skepticism on Efficacy
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug .... Payers are "always fumbling to reimburse [for rare disease drugs] as quickly as possible," said RBC Capital Markets analyst Simos Simeonidis, noting that the budget hit to any one payer from such a small patient group is better than an avalanche of bad publicity .... Xconomy

9/23 "Watchdogs Are Being Turned Into Lapdogs": Embargos Used to Control Reporters
How the FDA Manipulates the Media .... The U.S. Food and Drug Administration has been arm-twisting journalists into relinquishing their reportorial independence, our investigation reveals. Other institutions are following suit .... Scientific American

9/23 Celgene's New Indications for Abraxane Will Drive Growth Despite Generic Competition
Glenmark takes aim at Celgene's Abraxane with complex generic deal .... Glenmark has just signed a licensing deal with U.S. firm Particle Sciences for a generic version of Abraxane--an albumin-bound injectable formulation of paclitaxel--and says it plans to start filing the generic in 2019, starting with the U.S. market .... Fierce Pharma

9/23 State AGs Sue Suboxone Maker
Opioid Treatment Maker Accused of Illegally Blocking Generics .... The U.K. pharmaceutical company behind one of the best-selling treatments for opioid addiction -- a growing epidemic across the U.S. -- was sued by 36 states that claim it ripped off consumers by blocking a cheaper generic version of the drug .... Bloomberg

9/23 SNY Needs a Deal to Cover Diabetes Market Losses; May be Eyeing Regeneron
New Setback for Sanofi's Lantus Increases Need for M&A .... Sanofi has lost another round of its battle against generic interlopers in its key diabetes franchise, increasing the urgency for the French pharmaceuticals company to buy or launch new products following its failed run at oncology specialist Medivation .... The Street

9/23 It Usually Costs $800 to Find a Patient for a Parkinson's Study. On Facebook, You Can Find One for $35
The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study .... The MJFF's Facebook recruitment program, launched in January, is targeting participants based on their Facebook interests and preferences, ages, and proximity to metro areas with clinical study sites.... if Facebook members had interests associated with Judaism or Parkinson's disease, they were likely to have an ad about the clinical study pop up on their Facebook pages .... MM&M

9/23 Counterfeit Viagra Factory Shut Down in Poland
Polish police smash 'world's largest' fake Viagra plant .... A police swoop on a house near Bydgoszcz turned up machines worth a million euros installed in secret rooms that could only be accessed through hidden passages. .... Medical Xpress

9/23 Internet Drug News Fast Takes:
The Women's Health Issue No One Talks About
Kaiser Health News
Anthem, Cigna Have Accused Each Other of Merger Breach
Lundbeck says Alzheimer's drug fails in late-stage study
Drugs Can't Cure Alzheimer's. Could They Prevent It?
Bloomberg View
Potentially harmful chemicals widespread in household dust
George Washington University Milken Institute School of Public Health

9/22 Califf Calls for Retraction of Study That Was Basis for Eteplirsen Approval
Amid controversial Sarepta approval decision, FDA head calls for key study retraction .... In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients .... Retraction Watch

9/22 Lantus Out, Basaglar In at UnitedHealth
UnitedHealth trims drug coverage, including Sanofi insulin .... UnitedHealth said it is changing reimbursement terms for long-acting insulins and will no longer cover Lantus, the main insulin drug sold by Sanofi.... Basaglar, a cheaper biosimilar insulin sold by Eli Lilly & Co would be covered as "Tier 1" .... Reuters

9/22 Invokamet XR Approved
FDA Approves Invokamet XR for Treatment of Adults With Type-2 Diabetes .... Invokamet XR is a once-daily, fixed-dose combination of canagliflozin (Invokana), the most-prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, and an extended-release formulation of metformin .... PTCommunity

9/22 GSK Sticking to Antibiotics Research; A Facility Tour and Interviews with Principal Scientists
Why Superbugs Are Beating Big Pharma .... Just this month, AstraZeneca became the latest big pharmaceutical company to pull out of antibacterial drug development when it sold its antibiotics business to Pfizer Inc. GlaxoSmithKline is one of the few big players that's kept at it, sinking about $1 billion of its own money over the past decade into antibacterial research .... Bloomberg
See also: CDC: Too Many Antibiotics Still Being Prescribed in US [HealthDay]

9/22 $20 Billion in Cash in Its Pocket; Takeda Looking for Deals
Takeda's Biotech M&A Menu Is Long, Complex .... Takeda, Japan's largest pharma firm, is willing to spend up to $20 billion on acquisitions overseas .... Bloomberg Gadfly

9/22 Reuters 'Botox Police' Article Spurs Congressional Inquiry
House Committee probes FDA's criminal office after 'Botox Police' complaints .... In a Sept. 20 letter, committee chairman Fred Upton and Subcommittee on Oversight and Investigations chairman Tim Murphy posed a list of questions--including why the criminal office's director, George Karavetsos, runs the unit from a South Florida office near his home--to be answered by Oct. 12 .... Fierce Pharma

9/22 If You Like to Take a Flyer on a Drug Stock...
3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions .... Aerie Pharmaceuticals, Flexion Therapeutics, and Puma Biotechnology may have more running room ahead if regulators give their drugs the go-ahead. .... Motley Fool

9/22 Step Aside, Dr. Watson, Hanover is Here to Mix Cancer Cocktails
Microsoft Develops AI to Help Cancer Doctors Find the Right Treatments .... A Microsoft Research machine-learning project, dubbed Hanover, aims to ingest all the published research papers on cancer and help predict which drugs and which combinations are most effective .... Bloomberg

9/22 21st Century Cures Will Wait Till After Nov. 8
Medical cures bill pushed back to lame-duck .... House Energy and Commerce Committee Chairman Fred Upton is not planning to introduce a new version of his 21st Century Cures Act before the recess after all.... he is still hoping to get the legislation passed in the lame duck session .... The Hill

9/22 Real World Harvoni Price Averages $50,400 in U.S.
Surprise: Gilead's hep C wonder Harvoni costs less in U.S. than in EU, Japan .... According to a report from the IMS Institute for Healthcare Informatics, the combo drug Harvoni may have made its U.S. debut at a list price of $94,500, but after tough negotiations with payers, its net price comes to $50,400. .... Fierce Pharma

9/22 Blame on the Rebates
Blame Game: The $130 Billion in Fees Mylan Says Pushes Up Prices .... Rebates have more than doubled in four years to an estimated $100 billion to $130 billion today in the U.S. .... Bloomberg

9/22 Internet Drug News Fast Takes:
AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy
More Child Suicides Are Linked to A.D.D. Than Depression, Study Suggests
NY Times
Seniors still lagging in use of internet health resources
Reuters Health
Prescription painkillers are more widely used than tobacco, new federal study finds
Washington Post
Smoking Permanently Damages Your DNA
NBC News

9/21 First Female Head of Major Pharma Company
GlaxoSmithKline names insider Emma Walmsley as new CEO .... Walmsley, 47, joined Britain's biggest drugmaker in 2010 from L'Oreal and will replace Andrew Witty, who had previously announced his decision to retire on March 31, 2017 .... Reuters

9/21 Severe Fatty Liver Disease: Hot New Investment Area
Allergan Buys Liver Drug Maker Tobira, Sending Biotech Stocks Up .... Investors bet that buyers will emerge for other companies developing experimental treatments for a liver disease known as NASH. NASH, or non-alcoholic steatohepatitis, is a severe type of fatty liver disease that has become one of the hottest areas in biotech .... Bloomberg
See also: Allergan Buys Two Liver Disease Companies in Less Than a Day [Bloomberg]

9/21 Could Part D Direct Price Negotiations Really Work? A Look at the Chances
The Politics of Medicare and Drug-Price Negotiation .... The idea of authorizing Medicare Part D to negotiate directly with drug companies has received considerable media attention over the past few months and has broad public support, reflected in a recent poll showing 87 percent of Americans have a favorable view of the idea. .... Health Affairs

9/21 Carrey Denies Role in Abuse Death
Jim Carrey Lawsuit Shines Light On Prescription Drug Addiction in U.S. .... A new lawsuit claims actor Jim Carrey used his "immense wealth and celebrity status" to illegally obtain and distribute potentially deadly substances to his girlfriend Cathriona White, who died of a suicidal overdose at age 30 last year .... NBC News

9/21 Pulitizer-Prize Finalist Pharma Reporter Spent Hours Reading Internal FDA Documents Re: Sarepta, And Here's What He Found
Behind the Sarepta drug approval was intense FDA bickering .... "Woodcock's extensive, early involvement in the review process [was] troubling. Indeed, her involvement here appears to have upended the typical review and decision-making process." .... Stat/Pharmalot/Ed Silverman

9/21 13 Major Pharma Companies Pledge to Fend Off Superbugs
Drugmakers pledge to clean up antibiotic factories, curb overuse .... The group will work with independent experts to set new factory standards and review supply chains to ensure antibiotic waste does not enter waterways, where it can lead to the breeding of superbugs. .... Reuters

9/21 Repatha Shown to Kill Plaque. Meanwhile 2 out of 3 Prescriptions Are Denied by Payers
Amgen cholesterol drug reduces arterial plaque buildup .... In the 78-week study of 968 heart patients already on optimum statin therapy, Repatha lowered the percentage of atheroma volume in coronary arteries and demonstrated some plaque regression. .... Reuters

9/21 Painkiller Makers Fighting State by State to Protect Their Sales
Despite crisis, drugmakers work nationwide to fight opioid limits .... The makers of prescription painkillers have adopted a 50-state strategy that includes hundreds of lobbyists and millions of dollars in campaign contributions to help kill or weaken measures aimed at stemming the tide of prescription opioids .... USA Today

9/21 Promising New DPP-4 Inhibitor
Gemigliptin, metformin combo beats monotherapy in T2DM .... Researchers found that from baseline to week 24 the mean changes in HbA1c were −2.06 percent, −1.24 percent, and −1.47 percent, respectively, in the combination, gemigliptin monotherapy, and metformin monotherapy groups .... Medical Xpress

9/21 "Just One Pharmacy Pickup Per Month" Plan Improves Adherence
CVS Health's ScriptSync shows results .... Preliminary results, which tracked enrolled patients’ average days with medication per month using pharmacy claims data, indicated that the service improves medication adherence by an average of 5% to 10% .... Chain Drug Review

9/21 Internet Drug News Fast Takes:
Ariad Shares Rise Amid Speculation of Potential Buyout
Walgreens launches teledermatology service
Chain Drug Review
Employer Premiums Higher Than ACA Rates
Morning Consult
Bayer Raises Peak Sales Forecast for New-Medicine Portfolio
Hospitals Increasingly Employing Doctors, Effects on Care Uncertain

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 9/26/2016

If your intellectual property being infringed
e-mail the webmaster and we will fix it. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions. 

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!